# Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer

Source: https://onco.cc/trials/nct07691593/  
OnCo record `nct07691593` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Changhai Hospital, not yet recruiting.

## Summary

Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer is a phase 2, interventional study registered as NCT07691593 by Changhai Hospital, with a registry enrolment figure of 60 participants, started 2026-06 and due to reach its primary completion in 2027-10. Interventions recorded: HRS-4642+NALIRIFOX; HRS-4642+NALIRIFOX+Adebrelimab; HRS-4642+NALIRIFOX+Adebrelimab. Conditions listed: Pancreatic Cancer. Primary outcome: Adverse events (AEs); Objective Response Rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). Pancreatic eligibility wording from the registry: "Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07691593
- Phase: 2
- Setting: An Exploratory Clinical Study of HRS-4642 in Combination With Chemotherapy With or Without Adebrelimab as Neoadjuvant Therapy for Pancreatic Cancer
- Sponsor: Changhai Hospital
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07691593: https://clinicaltrials.gov/study/NCT07691593

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07691593.json